Glenmark Pharmaceuticals Limited (BOM:532296)
India · Delayed Price · Currency is INR 2,274.25
-108.40 (-4.55%)
At close: May 29, 2026
Glenmark Pharmaceuticals Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 13,619 | 10,471 | -15,017 | 2,972 | 9,417 |
Depreciation & Amortization | 5,735 | 3,594 | 4,792 | 3,810 | 1,613 |
Other Amortization | - | 1,266 | 1,517 | 2,303 | 3,254 |
Loss (Gain) From Sale of Assets | 170.18 | 25.42 | -8.26 | -57.25 | 64.64 |
Loss (Gain) From Sale of Investments | -0.25 | 0.27 | -7,450 | -0.26 | -149.81 |
Stock-Based Compensation | 268.05 | -91.67 | 49.62 | 67.74 | 79.16 |
Provision & Write-off of Bad Debts | 201.25 | 30.97 | 176.5 | 118.72 | 298.74 |
Other Operating Activities | 18,929 | 1,715 | 15,928 | 1,499 | 2,122 |
Change in Accounts Receivable | -17,505 | -14,203 | 9,695 | -8,487 | -5,493 |
Change in Inventory | -7,523 | -4,508 | -5,139 | -3,752 | -2,034 |
Change in Accounts Payable | 27,046 | -8,138 | -7,344 | 1,662 | 847.57 |
Change in Other Net Operating Assets | -6,489 | 1,562 | -5,182 | -167.73 | 1,067 |
Operating Cash Flow | 34,450 | -8,276 | -2,654 | 6,254 | 11,087 |
Operating Cash Flow Growth | - | - | - | -43.59% | -1.99% |
Capital Expenditures | -13,577 | -7,496 | -8,984 | -6,078 | -7,901 |
Sale of Property, Plant & Equipment | 23.3 | 24.2 | 20.8 | 572.29 | 15.8 |
Divestitures | - | 7,450 | 54,496 | - | - |
Investment in Securities | 305.69 | -93.03 | 70.51 | -10.08 | -100.18 |
Other Investing Activities | 415.75 | 135.16 | 5.31 | 230.51 | 4,653 |
Investing Cash Flow | -12,832 | 20.94 | 45,609 | -5,285 | -3,333 |
Short-Term Debt Issued | - | 8,339 | 4,811 | - | - |
Long-Term Debt Issued | - | 5,072 | - | 11,632 | 21,301 |
Total Debt Issued | - | 13,412 | 4,811 | 11,632 | 21,301 |
Short-Term Debt Repaid | -17,157 | - | - | -200 | -1,417 |
Long-Term Debt Repaid | -6,416 | -2,629 | -37,539 | -6,198 | -31,201 |
Total Debt Repaid | -23,573 | -2,629 | -37,539 | -6,398 | -32,618 |
Net Debt Issued (Repaid) | -23,573 | 10,783 | -32,728 | 5,234 | -11,317 |
Issuance of Common Stock | 7.59 | - | 12 | - | - |
Common Dividends Paid | -1,410 | -704.42 | -704.52 | -703.86 | -926.95 |
Other Financing Activities | -2,111 | -2,208 | -5,641 | -5,305 | 7,040 |
Financing Cash Flow | -27,087 | 7,870 | -39,061 | -774.56 | -5,205 |
Foreign Exchange Rate Adjustments | 459.59 | 558.93 | 176.79 | 123.87 | 175.5 |
Miscellaneous Cash Flow Adjustments | -0.04 | - | -1,918 | 6.68 | - |
Net Cash Flow | -5,010 | 174.37 | 2,152 | 325 | 2,724 |
Free Cash Flow | 20,873 | -15,772 | -11,638 | 176.29 | 3,185 |
Free Cash Flow Growth | - | - | - | -94.47% | -10.64% |
Free Cash Flow Margin | 11.97% | -11.80% | -9.20% | 0.15% | 2.59% |
Free Cash Flow Per Share | 73.94 | -55.89 | -41.24 | 0.63 | 11.29 |
Cash Interest Paid | - | 1,908 | 5,168 | 3,115 | 2,505 |
Cash Income Tax Paid | - | 6,801 | 10,475 | 6,405 | 5,584 |
Levered Free Cash Flow | 14,384 | -16,058 | 43,246 | -11,604 | 1,853 |
Unlevered Free Cash Flow | 15,689 | -14,764 | 46,471 | -9,423 | 3,716 |
Change in Working Capital | -4,471 | -25,287 | -7,970 | -10,745 | -5,613 |